Medical oncologist appointed chair of bladder cancer advisory board
Click Here to Manage Email Alerts
Elizabeth Plimack, MD, MS, has been appointed chair of Bladder Cancer Advocacy Network’s scientific advisory board.
Plimack is professor in the department of hematology/oncology and chief of the division of genitourinary medical oncology at Fox Chase Cancer Center. Her research has focused on identifying biomarkers for neoadjuvant cisplatin-based chemotherapy in bladder cancer, as well as immunotherapy and developmental therapeutics for genitourinary malignancies.
Plimack succeeds Gary D. Steinberg, MD, FACS, director of the Goldstein urology bladder cancer program at NYU Langone Health, who served as scientific advisory board chair for 11 years.
“We are pleased that Dr. Plimack has agreed to serve as the new chairperson of our [scientific advisory board],” Andrea Maddox-Smith, CEO of Bladder Cancer Advocacy Network (BCAN), said in a press release. “We welcome her leadership and strategic guidance on medical and clinical issues and also to ensure that BCAN’s programs and products are up to date, accurate and impartial.”
BCAN is a national organization dedicated to advancing bladder cancer care and research. Its scientific advisory board includes oncologists, radiation oncologists, urologists and pathologists.
“It has been an honor to serve BCAN over the last decade, and I am excited to take on this new role as chair of the scientific advisory board,” Plimack said in a press release. “We are fortunate in the field of bladder cancer to have created a culture of engagement and collaboration — for which BCAN as an organization deserves credit. I look forward to working with my fellow experts toward the shared goals of better understanding this disease and improving outcomes for our patients through science.”
Read more about
Click Here to Manage Email Alerts